Sandra Hanner | Authors


Novel IDO Inhibitor Yields Durable Responses in Metastatic Pancreatic Cancer

April 21, 2016

Novel therapy with indoximod, an indoleamine 2,3-dioxygenase (IDO) pathway inhibitor, in combination with standard chemotherapy, yielded a response rate of 42% as first-line therapy for metastatic pancreatic adenocarcinoma

Ensituximab Proves Promising in Refractory mCRC

April 14, 2016

Treatment with ensituximab (NPC-1C), a chimeric IgG1 monoclonal antibody, induced stable disease in nearly half of patients with chemotherapy-refractory metastatic colorectal cancer (mCRC) without contributing significant toxicity.

Ensituximab (NPC-1C) Shows Promise and Good Tolerability in Refractory Metastatic Colorectal Cancer

January 29, 2016

In patients with chemotherapy-refractory metastatic colorectal cancer (mCRC), ensituximab (NPC-1C), a chimeric immunoglobulin IgG1 monoclonal antibody, produced stable disease in almost half the patients in a phase II study, without contributing toxicity.

Analysis Shows Pancreatic Cancer Survival Rates Lower in Real World Than Clinical Trials

January 27, 2016

Patients with pancreatic adenocarcinoma enrolled on clinical trials have "profoundly improved survival" compared with patients in the general population, suggesting that oncologists who use trial data to prognosticate may be missing the mark, according to researchers whose work was presented at the 2016 Gastrointestinal Cancers Symposium.

Breast Cancer Patients Referred for Genetic Testing Likely to Have Mutations Other Than BRCA1/2

January 21, 2015

In an analysis of more than 17,000 patients with breast cancer, who are at risk for a genetic mutation, subjects were as likely to have a mutation in a gene other than BRCA1 and BRCA2 as they were to have these common mutations.